These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38831492)

  • 1. Is anchoring at 'dead' a theoretical requirement for health state valuation?
    Sampson C; Parkin D; Devlin N
    Health Econ; 2024 Sep; 33(9):1929-1935. PubMed ID: 38831492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dealing with the health state 'dead' when using discrete choice experiments to obtain values for EQ-5D-5L heath states.
    Ramos-Goñi JM; Rivero-Arias O; Errea M; Stolk EA; Herdman M; Cabasés JM
    Eur J Health Econ; 2013 Jul; 14 Suppl 1(Suppl 1):S33-42. PubMed ID: 23900663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values.
    Shah KK; Ramos-Goñi JM; Kreimeier S; Devlin NJ
    Eur J Health Econ; 2020 Sep; 21(7):1091-1103. PubMed ID: 32506281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of methods for converting DCE values onto the full health-dead QALY scale.
    Rowen D; Brazier J; Van Hout B
    Med Decis Making; 2015 Apr; 35(3):328-40. PubMed ID: 25398621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling ranking, time trade-off, and visual analog scale values for EQ-5D health states: a review and comparison of methods.
    Craig BM; Busschbach JJ; Salomon JA
    Med Care; 2009 Jun; 47(6):634-41. PubMed ID: 19433996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond 10-year lead-times in EQ-5D-5L: leveraging alternative lead-times in willingness-to-accept questions to capture preferences for worse-than-dead states and their implication.
    Chang JA; Hsu CN; Ramos-Goñi JM; Luo N; Lin HW; Lin FJ
    Eur J Health Econ; 2024 Aug; 25(6):1041-1055. PubMed ID: 38072877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparatory study for the revaluation of the EQ-5D tariff: methodology report.
    Mulhern B; Bansback N; Brazier J; Buckingham K; Cairns J; Devlin N; Dolan P; Hole AR; Kavetsos G; Longworth L; Rowen D; Tsuchiya A
    Health Technol Assess; 2014 Feb; 18(12):vii-xxvi, 1-191. PubMed ID: 24568945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Different DCE-Based Approaches When Anchoring Utility Scores.
    Norman R; Mulhern B; Viney R
    Pharmacoeconomics; 2016 Aug; 34(8):805-14. PubMed ID: 27034244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The gap effect: discontinuities of preferences around dead.
    Stalmeier PF; Busschbach JJ; Lamers LM; Krabbe PF
    Health Econ; 2005 Jul; 14(7):679-85. PubMed ID: 15744750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valuation of the EQ-5D-5L with composite time trade-off for the German population - an exploratory study.
    Ludwig K; von der Schulenburg JG; Greiner W
    Health Qual Life Outcomes; 2017 Feb; 15(1):39. PubMed ID: 28219389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A shortcut to mean-based time tradeoff tariffs for the EQ-5D?
    Rand-Hendriksen K; Augestad LA; Dahl FA; Kristiansen IS; Stavem K
    Med Decis Making; 2012; 32(4):569-77. PubMed ID: 22247424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of health state utility values derived using time trade-off, rank and discrete choice data anchored on the full health-dead scale.
    Brazier J; Rowen D; Yang Y; Tsuchiya A
    Eur J Health Econ; 2012 Oct; 13(5):575-87. PubMed ID: 21959651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries.
    Bernert S; Fernández A; Haro JM; König HH; Alonso J; Vilagut G; Sevilla-Dedieu C; de Graaf R; Matschinger H; Heider D; Angermeyer MC;
    Value Health; 2009; 12(5):750-8. PubMed ID: 19490564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International Valuation Protocol for the EQ-5D-Y-3L.
    Ramos-Goñi JM; Oppe M; Stolk E; Shah K; Kreimeier S; Rivero-Arias O; Devlin N
    Pharmacoeconomics; 2020 Jul; 38(7):653-663. PubMed ID: 32297224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does the Introduction of the Ranking Task in Valuation Studies Improve Data Quality and Reduce Inconsistencies? The Case of the EQ-5D-5L.
    Ramos-Goñi JM; Rand-Hendriksen K; Pinto-Prades JL
    Value Health; 2016 Jun; 19(4):478-86. PubMed ID: 27325340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. This Dead or That Dead: Framing Effects in the Evaluation of Health States.
    Jakubczyk M; Schneider P; Lipman SA; Sampson C
    Value Health; 2024 Jan; 27(1):95-103. PubMed ID: 37913922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in health state valuation in paediatric economic evaluation: are QALYs contraindicated?
    Ungar WJ
    Pharmacoeconomics; 2011 Aug; 29(8):641-52. PubMed ID: 21604821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A uniform time trade off method for states better and worse than dead: feasibility study of the 'lead time' approach.
    Devlin NJ; Tsuchiya A; Buckingham K; Tilling C
    Health Econ; 2011 Mar; 20(3):348-61. PubMed ID: 21308856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Censoring Time Trade-off Values at 0 Versus at -1: How Does the Assumption for Worse-Than-Dead Time Trade-off Values Affect the Modeling of EQ-5D-5L Valuation Data?
    Yang Z; Rand K; Luo N
    Value Health; 2023 May; 26(5):685-693. PubMed ID: 36375679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.